<DOC>
	<DOC>NCT02041221</DOC>
	<brief_summary>Sun Pharma Advanced Research company Limited has developed a dry powder inhaler of compound SPARC1316 for oral inhalation. This clinical study is a Phase I/IIa study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of S0597 administered by oral inhalation to healthy volunteers and asthma patients.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316</brief_title>
	<detailed_description />
	<criteria>Subjects willing to provide informed consent Male or female subjects aged 18 to 65 years inclusive Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive Nonsmokers or exsmokers Subjects with a supine systolic blood pressure ≥160 mmHg and/or a supine diastolic blood pressure ≥100 mmHg Subjects who have a significant infection or known inflammatory process on screening or admission. Subjects who are unlikely to cooperate with the requirements of the study. Positive serology for infectious disease (hepatitisB or C , HIV) at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pharmacokinetics, pharmacodynamics, asthma</keyword>
</DOC>